𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Expression and Characterization of Hepatitis B Virus Precore-Core Antigen in E. coli

✍ Scribed by LANFORD, ROBERT E.; NOTVALL, LENA M.; DREESMAN, GORDON R.; HARRISON, CHANTAL R.; LOCKWOOD, DON; BURK, KENNETH H.

Book ID
118040436
Publisher
Mary Ann Liebert
Year
1987
Tongue
English
Weight
614 KB
Volume
1
Category
Article
ISSN
0882-8245

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Evolution of precore/core promoter mutat
Evolution of precore/core promoter mutations in hepatitis B carriers with hepatitis B e antigen seroreversion
✍ Chun-Jen Liu; Pei-Jer Chen; Ming-Yang Lai; Prof. Jia-Horng Kao; Ding-Shinn Chen 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 154 KB 👁 1 views

## Abstract The evolution of precore stop codon mutation (A1896) and dinucleotide mutation (T1762/A1764) in the basic core promoter (BCP) of hepatitis B virus (HBV) genome during transient seroconversion and seroreversion of hepatitis B e antigen (HBeAg) remains unclarified. Five HBeAg‐positive HBV

Efficacy of lamivudine in patients with
Efficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis BB
✍ Nicolaos C. Tassopoulos; Riccardo Volpes; Giuseppe Pastore; Jenny Heathcote; Mar 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 152 KB 👁 1 views

This placebo controlled, double-blind study evaluated the efficacy and safety of lamivudine in patients with hepatitis B e antigen (HBeAg)-negative/hepatitis B virus (HBV) DNA-positive chronic hepatitis B. Patients were randomized to receive 100 mg lamivudine orally once daily for 52 weeks (n ‫؍‬ 60